According to a 2025 report on Cataract Surgery Devices Market by Mordor Intelligence, the global market is expected to grow from USD 8.90 billion in 2025 to USD 10.

Learn more at www.alcon.com. µ Results from a prospective, randomized, parallel group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof ® IQ Vivity ...

‖ AcrySof ® IQ Vivity ® was tested. Clinical studies were performed on the AcrySof ® IQ Vivity ® IOL; AcrySof ® IQ Vivity ® and Clareon ® Vivity ® are optically equivalent.

After implantation of the AcrySof IQ Toric IOL in the capsular bag, the lens was rotated and aligned to the ink marks and finally pushed back to the posterior capsule to ensure proper and durable ...

Its AcrySof IQ is the most implanted IOL in the world; recent notable launches in the space include PanOptix and Vivity, both first of their kind in the United States.

Alcon has unveiled data from the study of the AcrySof IQ Vivity and the AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens.

Also available in toric designs, Vivity is built on Alcon’s trusted and proven AcrySof IQ IOL platform that has been implanted in more than 125 million eyes globally.5 According to results from ...

(2021-01-07) Alcon Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S.

Available in spherical and toric designs, AcrySof ® IQ Vivity ® is built on Alcon's proven AcrySof ® IQ platform that has been implanted in more than 120 million eyes globally.